| scholarly article | Q13442814 |
| P50 | author | Berthold Huppertz | Q56256895 |
| P2093 | author name string | Hamutal Meiri | |
| Sveinbjörn Gizurarson | |||
| Maurizio Mandalá | |||
| Tijana Drobnjak | |||
| P2860 | cites work | Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein | Q22010697 |
| A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death | Q24317162 | ||
| Placental Protein 13 (PP13) - A Placental Immunoregulatory Galectin Protecting Pregnancy | Q26861380 | ||
| Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia | Q28081459 | ||
| Galectins. Structure and function of a large family of animal lectins | Q28246794 | ||
| Functional analyses of placental protein 13/galectin-13 | Q28249207 | ||
| Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17) | Q28275001 | ||
| PP13, maternal ABO blood groups and the risk assessment of pregnancy complications | Q28742192 | ||
| New developments in the pathogenesis of preeclampsia | Q33935675 | ||
| Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study | Q33947553 | ||
| Retracted: The Role of the Carbohydrate Recognition Domain of Placental Protein 13 (PP13) in Pregnancy Evaluated with Recombinant PP13 and the DelT221 PP13 Variant | Q33981931 | ||
| Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia | Q34328411 | ||
| Placental Protein 13 and Decidual Zones of Necrosis: An Immunologic Diversion That May be Linked to Preeclampsia | Q56794716 | ||
| Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia | Q61826576 | ||
| Maternal serum placental protein 13 at 11â 13 weeks of gestation in preeclampsia | Q61847857 | ||
| Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia | Q61865449 | ||
| An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation | Q72135926 | ||
| First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia | Q79409207 | ||
| The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model | Q80328418 | ||
| Pre-eclampsia | Q81446389 | ||
| A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound | Q82068160 | ||
| PP13 stability in first trimester maternal serum and whole blood | Q84321060 | ||
| Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women | Q84689681 | ||
| Blood groups in rabbits | Q95820199 | ||
| First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction | Q34647428 | ||
| First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia | Q35124240 | ||
| Mechanistic determinants of biotherapeutics absorption following SC administration. | Q36065572 | ||
| Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. | Q37416997 | ||
| An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. | Q38305281 | ||
| Long-term mortality after preeclampsia | Q38475210 | ||
| Placental Protein 13 Administration to Pregnant Rats Lowers Blood Pressure and Augments Fetal Growth and Venous Remodeling | Q38969936 | ||
| Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents | Q45783688 | ||
| Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age. | Q50879778 | ||
| Placental protein 13 (PP13)-induced vasodilation of resistance arteries from pregnant and nonpregnant rats occurs via endothelial-signaling pathways. | Q50992588 | ||
| The ABO blood group system: historical background. | Q53475062 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1977-1983 | |
| P577 | publication date | 2018-07-03 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits. | |
| P478 | volume | 12 |
| Q64112776 | Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration | cites work | P2860 |
Search more.